HighField to Present Preclinical Data on mRNA GLP-1R Agonist for Diabetes at ADA's 84th Session

HighField Biopharmaceuticals, a clinical-stage company based in Hangzhou, China, is pioneering innovative treatments for conditions such as cancer and diabetes using lipid-based therapeutics. Recently, the company's preclinical research on an mRNA-based GLP-1R agonist (HFG1) demonstrated promising results in diabetic monkeys. This research has been recognized by the American Diabetes Association (ADA) and will be showcased at their 84th Scientific Sessions, scheduled to take place from June 21-24, 2024, in Orlando, Florida. The findings will also be published on the ADA’s journal, Diabetes, website.

Dr. Yuhong Xu, CEO and Scientific Founder of HighField, expressed enthusiasm about presenting their novel lipid nanoparticle (LNP)-mRNA complex, HFG1, to a global audience of clinicians and researchers at the ADA event. Dr. Xu highlighted the innovative design of HFG1’s LNP complex, which aims to provide a consistent expression of the GLP-1R agonist for diabetes management and weight loss. A key advantage of HFG1 is its potential to reduce the frequency of injections compared to existing GLP-1 products, while maintaining steady-state agonist activity.

The poster presentation, titled "Preliminary Study of Efficacy and Duration of an mRNA-Based GLP-1R Agonist in Diabetic Monkeys," will be presented by Dr. Yuhong Xu on Saturday, June 22, 2024, between 12:30 PM and 1:30 PM EDT. The poster will remain on display throughout the weekend in the Poster Hall, with an opportunity for networking on Friday evening.

HighField Biopharmaceuticals specializes in creating liposome constructs designed to disrupt current immuno-oncology and disease treatment technologies. The company operates a research and development center alongside a GMP-compliant production facility. Its leading clinical development initiative is HF1K16, a liposome-encapsulated immune-modulating drug containing all-trans retinoic acid, targeted at myeloid-derived suppressor cells for solid tumor treatment. Additionally, their pipeline features drug-encapsulated immunoliposomes for various solid tumor cancers and lipid therapeutics aimed at gene delivery and gene therapy.

In terms of future plans, HighField intends to file a U.S. IND for HFG1 in the third quarter of 2024, marking a significant step towards clinical trials and potential commercialization. The acceptance of their abstract for presentation at the ADA conference underscores the importance and potential impact of their innovative approach to diabetes treatment.

By focusing on lipid-based delivery systems, HighField is positioned at the forefront of developing more effective and less invasive treatment options for chronic diseases, leveraging the latest advancements in mRNA technology and nanoparticle delivery systems. The company's commitment to advancing therapeutic solutions underscores its potential to make significant contributions to the field of biopharmaceuticals.